초록 ▼

The present invention is concerned with a combination for the preservation of diagnostic tests, characterized by a content of at least two components selected from the group comprising 2-methyl-4-isothiazolin-3-one hydrochloride, 2-hydroxypyridine-N-oxide, chloroacetamide, (N,N-methylene-bis-(N-(1-h

The present invention is concerned with a combination for the preservation of diagnostic tests, characterized by a content of at least two components selected from the group comprising 2-methyl-4-isothiazolin-3-one hydrochloride, 2-hydroxypyridine-N-oxide, chloroacetamide, (N,N-methylene-bis-(N-(1-hydroxymethyl-2,5-dioxo-4-imidazolidinyl))-urea and 5-bromo-5-nitro-1,3-dioxan. The present invention is also concerned with a preserved diagnostic test kit, comprising test reagents and at least two preservation agents selected from the group comprising 2-methyl-4-isothiazolin-3-one hydrochloride, 2-hydroxypyridine-N-oxide, chloroacetamide, (N,N-methylene-bis-(N-(1-hydroxymethyl)-2,5-dioxo-4-imidazolidinyl))-urea and 5-bromo-5-nitro-1,3-dioxan.

대표청구항 ▼

In a diagnostic test kit containing diagnostic test reagents for determination of an analyte the improvement comprising a preservation reagent in said diagnostic test reagents or in a buffer solution, wherein said preservation reagent consists of 2-hydroxypyridine-N-oxide in an active concentration

In a diagnostic test kit containing diagnostic test reagents for determination of an analyte the improvement comprising a preservation reagent in said diagnostic test reagents or in a buffer solution, wherein said preservation reagent consists of 2-hydroxypyridine-N-oxide in an active concentration of from 0.1 to 0.5% and at least one other reagent selected from the group consisting of 2-methyl-4-isothiazoline-3-one hydrochloride, chloroacetamide, (N,N-methylene-bis-(N-1-hydroxymethyl)-2,5-dioxo-4-imidazolidinyl))-urea and 5-bromo-5-nitro-1,3-dioxane.